{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:01:12Z","timestamp":1781107272891,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Several cancer types have increased PFKFB3, a glycolytic enzyme for which potent inhibitors have been found. Inhibition of PFKFB3 impairs DNA repair after irradiation of cancer cells, making it a possible radiosensitization target. The SweBCG91RT trial, in which breast cancer patients were randomized to postoperative radiotherapy or not, was used to investigate PFKFB3 as a clinical marker of sensitivity to adjuvant radiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Nuclear protein levels of PFKFB3 were assessed with immunohistochemistry in primary breast tumors (<jats:italic>n<\/jats:italic>\u2009=\u2009970) and whole-cell RNA levels with microarray gene expression (<jats:italic>n<\/jats:italic>\u2009=\u2009765). Multivariable competing risks regression analysis was employed for the effect of radiotherapy on incidence of ipsilateral breast tumor recurrence (IBTR), depending on PFKFB3 levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Tumors with high levels of nuclear protein and RNA had the largest effect on incidence of IBTR of adjuvant radiotherapy, however without evidence of an interaction. <jats:italic>PFKFB3<\/jats:italic> RNA correlated with subtype, as high levels were more common among the human epidermal growth factor receptor 2 (HER2) positive and Luminal A subtypes than Luminal B and triple negative tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>High PFKFB3 is associated with a larger reduction of IBTR after radiotherapy but PFKFB3 cannot reliably be used as a predictive marker of sensitivity to adjuvant radiotherapy in breast cancer. <jats:italic>PFKFB3<\/jats:italic> expression differed with subtype, indicating that it may be a better marker among Luminal A and HER2 positive tumors, but this is yet to be investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The trial has been retrospectively registered at clinicaltrials.gov 2024-10-03 (NCT06637202).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13703-1","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:39:50Z","timestamp":1740735590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up"],"prefix":"10.1186","volume":"25","author":[{"given":"Moa","family":"Egelberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Pekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrika","family":"Killander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nim\u00e9us","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"9804","key":"13703_CR1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"S Darby","year":"2011","unstructured":"Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707\u201316.","journal-title":"Lancet"},{"key":"13703_CR2","unstructured":"Odle TG. Adverse effects of breast cancer treatment. Radiol Technol. 2014;85(3):297\u00a0M-319\u00a0M; quiz 20\u00a0M-23\u00a0M."},{"issue":"4","key":"13703_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41419-018-0435-y","volume":"9","author":"WK Shi","year":"2018","unstructured":"Shi WK, Zhu XD, Wang CH, Zhang YY, Cai H, Li XL, et al. PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT. Cell Death Dis. 2018;9(4):428.","journal-title":"Cell Death Dis"},{"issue":"1","key":"13703_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-016-3968-8","volume":"160","author":"J O\u2019Neal","year":"2016","unstructured":"O\u2019Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2\u2009+\u2009breast cancer. Breast Cancer Res Treat. 2016;160(1):29\u201340.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"13703_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.oooo.2021.02.005","volume":"132","author":"J Li","year":"2021","unstructured":"Li J, Tang X. Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(1):57\u201365.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"7","key":"13703_CR6","doi-asserted-by":"publisher","first-page":"e00377","DOI":"10.14309\/ctg.0000000000000377","volume":"12","author":"L Lei","year":"2021","unstructured":"Lei L, Hong LL, Ling ZN, Zhong Y, Hu XY, Li P, Ling ZQ. A potential oncogenic role for PFKFB3 overexpression in gastric Cancer progression. Clin Transl Gastroenterol. 2021;12(7):e00377.","journal-title":"Clin Transl Gastroenterol"},{"issue":"20","key":"13703_CR7","first-page":"5881","volume":"62","author":"T Atsumi","year":"2002","unstructured":"Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, et al. High expression of inducible 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;62(20):5881\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"13703_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jb\/mvh137","volume":"136","author":"M Fukasawa","year":"2004","unstructured":"Fukasawa M, Tsuchiya T, Takayama E, Shinomiya N, Uyeda K, Sakakibara R, Seki S. Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase gene. J Biochem. 2004;136(3):273\u20137.","journal-title":"J Biochem"},{"key":"13703_CR9","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/sigtrans.2017.44","volume":"2","author":"L Shi","year":"2017","unstructured":"Shi L, Pan H, Liu Z, Xie J, Han W. Roles of PFKFB3 in cancer. Signal Transduct Target Ther. 2017;2:17044.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"13703_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1535-7163.MCT-07-0482","volume":"7","author":"B Clem","year":"2008","unstructured":"Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7(1):110\u201320.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"13703_CR11","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1038\/s41467-018-06287-x","volume":"9","author":"NMS Gustafsson","year":"2018","unstructured":"Gustafsson NMS, Farnegardh K, Bonagas N, Ninou AH, Groth P, Wiita E, et al. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 2018;9(1):3872.","journal-title":"Nat Commun"},{"issue":"8","key":"13703_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","volume":"12","author":"BF Clem","year":"2013","unstructured":"Clem BF, O\u2019Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 2013;12(8):1461\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"36","key":"13703_CR13","doi-asserted-by":"publisher","first-page":"24223","DOI":"10.1074\/jbc.M109.016816","volume":"284","author":"A Yalcin","year":"2009","unstructured":"Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 2009;284(36):24223\u201332.","journal-title":"J Biol Chem"},{"issue":"12","key":"13703_CR14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0959-8049(03)00324-1","volume":"39","author":"P Malmstr\u00f6m","year":"2003","unstructured":"Malmstr\u00f6m P, Holmberg L, Anderson H, Mattsson J, J\u00f6nsson PE, Tennvall-Nittby L, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003;39(12):1690\u20137.","journal-title":"Eur J Cancer"},{"key":"13703_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2016.08.001","volume":"67","author":"F Killander","year":"2016","unstructured":"Killander F, Karlsson P, Anderson H, Mattsson J, Holmberg E, Lundstedt D, et al. No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. Eur J Cancer. 2016;67:57\u201365.","journal-title":"Eur J Cancer"},{"issue":"28","key":"13703_CR16","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1200\/JCO.2017.72.7263","volume":"35","author":"M Sj\u00f6str\u00f6m","year":"2017","unstructured":"Sj\u00f6str\u00f6m M, Lundstedt D, Hartman L, Holmberg E, Killander F, Kov\u00e1cs A, et al. Response to Radiotherapy after breast-conserving surgery in different breast Cancer subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. J Clin Oncol. 2017;35(28):3222\u20139.","journal-title":"J Clin Oncol"},{"issue":"35","key":"13703_CR17","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.19.00761","volume":"37","author":"M Sj\u00f6str\u00f6m","year":"2019","unstructured":"Sj\u00f6str\u00f6m M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, et al. Clinicogenomic Radiotherapy Classifier Predicting the need for intensified Locoregional Treatment after breast-conserving surgery for early-stage breast Cancer. J Clin Oncol. 2019;37(35):3340\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13703_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765\u201373.","journal-title":"Eur J Epidemiol"},{"key":"13703_CR19","unstructured":"Sweden S. Description of the register; Total population Register scb.se2017 [2024-01-10]. Available from: https:\/\/www.scb.se\/contentassets\/8f66bcf5abc34d0b98afa4fcbfc0e060\/rtb-bar-2016-eng.pdf"},{"issue":"9","key":"13703_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"issue":"5","key":"13703_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403\u201310.","journal-title":"Histopathology"},{"issue":"6","key":"13703_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ygeno.2012.08.003","volume":"100","author":"SR Piccolo","year":"2012","unstructured":"Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics. 2012;100(6):337\u201344.","journal-title":"Genomics"},{"issue":"446","key":"13703_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"13703_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1536867X0400400201","volume":"4","author":"V Coviello","year":"2004","unstructured":"Coviello V, Boggess M. Cumulative incidence estimation in the Presence of competing risks. Stata J. 2004;4(2):103\u201312.","journal-title":"Stata J"},{"issue":"43","key":"13703_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"13703_CR26","first-page":"945","volume":"52","author":"F Peng","year":"2018","unstructured":"Peng F, Li Q, Sun JY, Luo Y, Chen M, Bao Y. PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. Int J Oncol. 2018;52(3):945\u201354.","journal-title":"Int J Oncol"},{"issue":"13","key":"13703_CR27","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1074\/jbc.M113.529990","volume":"289","author":"Y Imbert-Fernandez","year":"2014","unstructured":"Imbert-Fernandez Y, Clem BF, O\u2019Neal J, Kerr DA, Spaulding R, Lanceta L, et al. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem. 2014;289(13):9440\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"13703_CR28","doi-asserted-by":"publisher","first-page":"e1419","DOI":"10.1210\/clinem\/dgz117","volume":"105","author":"RA Chi","year":"2020","unstructured":"Chi RA, Wang T, Adams N, Wu SP, Young SL, Spencer TE, DeMayo F. Human endometrial transcriptome and progesterone receptor cistrome reveal important pathways and epithelial regulators. J Clin Endocrinol Metab. 2020;105(4):e1419\u201339.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"13703_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jcb.30443","volume":"124","author":"A Kashyap","year":"2023","unstructured":"Kashyap A, Umar SM, Dev JRA, Mathur SR, Gogia A, Batra A, et al. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis. J Cell Biochem. 2023;124(9):1259\u201372.","journal-title":"J Cell Biochem"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13703-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:40:08Z","timestamp":1740735608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13703-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13703"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13703-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original trial and the subsequent follow-up and TMA creation were approved by the Regional Ethical Review Board at Lund University (approval numbers 80\/90, 2010\/127, and 2015\/548). Patients gave informed oral consent and the study followed the standards set by the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Erik Holmberg and Per Karlsson have contracts with Exacts Sciences and Prelude DX regarding IP\/patents, not related to the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}